Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results.

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study by Samantha Pozzi, Stefania Badiali, Alessandro Corso, Pellegrino Musto, Attilio Guarini, Carla Minoia, Donatella Vincelli, Roberto Ria, Luciano Masini, Giovanni Quarta, Massimo Gentile, Carla Mazzone, Antonio Palumbo, and Fortunato Morabito Blood Volume 122(21): November 15, 2013 ©2013 by American Society of Hematology

Duration of remission. Duration of remission. Kaplan-Meier estimates (in months) with 95% CI of DR in 28 patients treated with BdL for relapsed MM. Samantha Pozzi et al. Blood 2013;122:3212 ©2013 by American Society of Hematology

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results.

Presentazioni simili

Presentazione sul tema: "Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results."— Transcript della presentazione:

Presentazioni simili

Sul progetto

Feed-back

Entrare

Autorizzarsi attraverso i social network:

Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results.

Presentazioni simili

Presentazione sul tema: "Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results."— Transcript della presentazione:

Presentazioni simili

Sul progetto

Feed-back